About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Venue Information

The Union League of Philadelphia 140 South Broad Street Philadelphia, PA 19102 Tel: (215) 405-9578 www.unionleague.org/

Add to your Calendar





Who Should Attend


The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • Scholar Rock raises $20M series AScholar Rock LLC (Cambridge, Mass.) raised $20 million in a series A round led by new investor ARCH Venture Partners. Founding investors Polaris Partners and Timothy Springer joined new investors EcoR1 Capital and The Kraft Group in the round.

    Scholar Rock is developing biologics that modulate the activation of growth factors in disease microenvironments. The company is investigating preclinical programs to treat fibrosis, musculoskeletal diseases and autoimmune disorders.

    Scholar Rock also hired Elan Ezickson as its first COO and head of corporate development. Ezickson formerly was EVP and COO of Aveo Pharmaceuticals Inc. (NASDAQ:AVEO).

    In January, the Boston Innovation Center of Johnson & Johnson (NYSE:JNJ) and J&J's Janssen Biotech Inc. unit partnered with Scholar Rock to discover and develop niche activators targeting transforming growth factor (TGF) beta 1 (TGFB1) for autoimmune diseases and cancer (see BioCentury, Jan. 13).
Read more

Industry News from PharmAsia

Read more

Upcoming Supporter Events


Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel
Philadelphia, PA

Read more